治疗心脏性休克管理的治疗进展
Radu Filipescu1,2, Sean P Collins3, Razvan I Radu1,2
1Intensive Cardiac Care Unit, Emergency Institute for Cardiovascular Diseases "C. C. Iliescu", Bucharest, Romania.
American journal of therapeutics
|January 16, 2026
概括
心脏性休克 (CS) 管理已经取得了进展,但高死亡率仍然存在. 早期的再血管化和特定的机械循环支持 (MCS) 是有希望的,但对于个性化CS治疗,更多的研究是至关重要的.
科学领域:
- 心脏病学 心脏病学
- 临界护理医学 临界护理医学
背景情况:
- 心脏性休克 (CS) 管理仍然具有挑战性,尽管目前的治疗方法仍然存在高死亡率.
- 在早期CS管理,风险分层和机械循环支持 (MCS) 启动方面存在重大不确定性.
研究的目的:
- 审查心脏性休克管理中的治疗进展.
- 突出需要进一步研究和临床调查的领域.
主要方法:
- 这篇叙事综述综合了来自多中心注册表和随机对照试验 (RCT) 的证据.
- 专注于最近的研究和正在进行的CS管理研究.
主要成果:
- 在急性心肌梗塞相关的CS (AMI-CS) 和肺动脉导管使用的早期再血管化改善了监测.
- 无otropes和血管压缩剂缺乏RCT证据证明生存益处;临时的MCS,特别是微轴流,在特定人群中显示出潜力.
- 枢纽和分支模型可以促进区域CS网络.
结论:
- 目前的CS治疗方法改善了预后,但需要进一步研究.
- 解决知识差距对于推进个性化CS治疗至关重要.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
675
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
675
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480


